Markers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health Study

Parkinsonism and Related Disorders

Volumn 18, Issue 3, 2012, Pages 274-278

  Ton, Thanh G N ^a   Jain, Samay ^b   Biggs, Mary L ^c   Thacker, Evan L ^c   Strotmeyer, Elsa S ^d   Boudreau, Robert ^d   Newman, Anne B ^d   Longstreth, W T ^a,c   Checkoway, Harvey ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Albumins; C reactive protein; Inflammation; Interleukin 6; Odds ratio; Parkinson's disease; Tumor necrosis factor

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICAN; AGE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR HEALTH STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; TYPES OF STUDY;

AGED; AGED, 80 AND OVER; ALBUMINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; HUMANS; INCIDENCE; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; PARKINSON DISEASE; PREVALENCE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857442573     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.11.003     Document Type: Article

References (27)

1. Lee J.K., Tran T., Tansey M.G. Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009, 4:419-429.
2. Chung Y.C., Ko H.W., Bok E., Park E.S., Huh S.H., Nam J.H., et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010, 43:225-232.
3. 11C]-PK11195 PET. Mov Disord 2007, 22:1852-1856.
4. Nagatsu T., Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 2007, 113-120.
5. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000, 60:277-290.
6. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100:34-41.
7. Stypula G., Kunert-Radek J., Stepien H., Zylinska K., Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation 1996, 3:131-134.
8. Dufek M., Hamanova M., Lokaj J., Goldemund D., Rektorova I., Michalkova Z., et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:318-320.
9. Chen H., O'Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008, 167:90-95.
10. Wong K.T., Grove J.S., Grandinetti A., Curb J.D., Yee M., Blanchette P., et al. Association of fibrinogen with Parkinson disease in elderly Japanese-American men: a prospective study. Neuroepidemiology 2009, 34:50-54.
11. Fried L.P., Borhani N.O., Enright P., Furberg C.D., Gardin J.M., Kronmal R.A., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991, 1:263-276.
12. Cushman M., Cornell E.S., Howard P.R., Bovill E.G., Tracy R.P. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995, 41:264-270.
13. Keller C., Katz R., Sarnak M.J., Fried L.F., Kestenbaum B., Cushman M., et al. Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 2010, 25:119-124.
14. Klegeris A., McGeer P.L. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005, 2:355-365.
15. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997, 43:52-58.
16. Ton T.G., Jain S., Boudreau R., Thacker E.L., Strotmeyer E.S., Newman A., et al. Post-doc Parkinson's: identifying an uncommon disease in the Cardiovascular Health Study. Neuroepidemiology 2010, 35:241-249.
17. Corportation S Stata statistical software, release 11.1 2005, Stata Corporation LP, College Station, TX.
18. Hald A., Van Beek J., Lotharius J. Inflammation in Parkinson's disease: causative or epiphenomenal?. Subcell Biochem 2007, 42:249-279.
19. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007, 205:295-312.
20. Song I.U., Chung S.W., Kim J.S., Lee K.S. Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease. Neurol Sci 2010.
21. Orr C.F., Rowe D.B., Mizuno Y., Mori H., Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-2674.
22. Song I.U., Kim J.S., Chung S.W., Lee K.S. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals. Eur Neurol 2009, 62:99-104.
23. Kritchevsky S.B., Cesari M., Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res 2005, 66:265-275.
24. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005, 18:315-321.
25. McGeer P.L., McGeer E.G. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 2004, 1035:104-116.
26. Minghetti L., Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998, 54:99-125.
27. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007, 150:963-976.